| Name | Title | Contact Details |
|---|
RSi Communications Group is a Hackensack, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Impact Advisors is a nationally recognized healthcare consulting firm that is solving some of the toughest challenges in the industry by delivering strategic advisory, implementation and optimization services. Our comprehensive suite of patient access, clinical and revenue cycle services span the lifecycle of our clients` needs. Our experienced team has a powerful combination of clinical, revenue, operations, consulting, and IT experience. The firm has earned a number of prestigious industry and workplace awards including Best in KLAS® for thirteen consecutive years, Healthcare Informatics HCI 100, Crain`s Chicago Business Fast Fifty, as well as multi-year “best place to work” awards from: Modern Healthcare, Consulting Magazine, Becker`s Hospital Review and Achievers.
Provation is a leading provider of clinical productivity software for healthcare professionals, with solutions for intelligent procedure documentation (Provation® MD and Provation® Apex), order set and care plan management (Provation® Order Sets and Provation® Care Plans), and EHR-embedded clinical documentation templates (Provation® Clinic Note). Our software helps providers increase operational efficiencies, business profitability and regulatory compliance by improving quality, streamlining workflows and enabling the generation of insights. Trusted by leading physicians globally, we serve approximately 1,500 hospitals and 1,000 ambulatory surgery centers (ASCs), including 16 of the top 20 U.S. hospitals for gastroenterology (GI) and GI surgery. Provation is headquartered in Minneapolis, MN and is owned by Clearlake Capital Group, L.P.
Making an impact on rare and serious skin and connective tissue diseases Fibrocell Science is at the forefront of the exciting and promising field of personalized biologics. By extracting cells from skin to create localized therapies that are compatible with the unique biology of each patient, personalized biologics bring a transformational approach to drug development. It is Fibrocell’s scientific leadership and legacy in cultivating and harnessing autologous fibroblast cells that fuels its personalized biologics approach. Fibrocell’s proprietary technology uses a person’s own fibroblast cells – with or without genetic modification – to target localized treatment of rare and serious skin and connective tissue diseases.
VNA of Rhode Island is a Warwick, RI-based company in the Healthcare, Pharmaceuticals, & Biotech sector.